Literature DB >> 7018671

Sensitivity of N-nitrosomethylurea-induced rat mammary tumors to cis-hydroxyproline, an inhibitor of collagen production.

W M Lewko, L A Liotta, M S Wicha, B K Vonderhaar, W R Kidwell.   

Abstract

The growth of primary N-nitrosomethylurea-induced rat mammary tumors was depressed by cis-hydroxyproline (CHP). This growth arrest appeared to be related to the ability of CHP to inhibit the deposition of basement membrane collagen as based on the following observations: (a) in vitro and in vivo, tumor cells synthesized type IV collagen, the collagen uniquely localized in basement membranes; (b) in vitro, the inhibition of tumor cell growth was preceded by a specific decrease in collagen accumulation with no effect on non-collagen protein synthesis; (c) a transplantable N-nitrosomethylurea-induced rat mammary tumor accumulated no type IV collagen as determined by polyacrylamide gel electrophoresis and indirect immunofluorescence. The growth of this tumor was not influenced by CHP; (d) an established human mammary tumor cell line, MCF-7, did not accumulate type IV collagen and was not inhibited by CHP. At the doses which effectively blocked the growth of primary N-nitrosomethylurea-induced mammary tumors, CHP and no toxic effects, and serum prolactin levels were not altered. The inhibitory effect was thus apparently due to the direct action of CHP upon the accumulation of collagen in cells which required type IV collagen production for continued growth.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7018671

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

Review 1.  The potential influence of radiation-induced microenvironments in neoplastic progression.

Authors:  M H Barcellos-Hoff
Journal:  J Mammary Gland Biol Neoplasia       Date:  1998-04       Impact factor: 2.673

2.  Keratinocytes grown at the air-liquid interface.

Authors:  L I Bernstam; F L Vaughan; I A Bernstein
Journal:  In Vitro Cell Dev Biol       Date:  1986-12

Review 3.  Angiogenesis: possibilities for therapeutic interventions.

Authors:  W Wynendaele; A T van Oosterom; A Pawinski; E A de Bruijn; R A Maes
Journal:  Pharm World Sci       Date:  1998-12

4.  Pharmacological therapy for proliferative vitreoretinopathy.

Authors:  N D Radtke; A D Weinsieder; R J Ballou
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1986       Impact factor: 3.117

5.  Cis-hydroxyproline-induced inhibition of pancreatic cancer cell growth is mediated by endoplasmic reticulum stress.

Authors:  Christoph Mueller; Joerg Emmrich; Robert Jaster; Dagmar Braun; Stefan Liebe; Gisela Sparmann
Journal:  World J Gastroenterol       Date:  2006-03-14       Impact factor: 5.742

6.  Cultured cell lines from human breast cancer biopsies and xenografts.

Authors:  W M Lewko; R Vaghmar; D Hubbard; M Moore; Y J He; L Chang; S Husseini; K Wallwork; G B Thurman; R K Oldham
Journal:  Breast Cancer Res Treat       Date:  1990-12       Impact factor: 4.872

7.  Growth of cells on a perfluorocarbon-medium interphase: a quantitative assay for anchorage-independent cell growth.

Authors:  B Sanfilippo; F Ciardiello; D S Salomon; W R Kidwell
Journal:  In Vitro Cell Dev Biol       Date:  1988-01

Review 8.  Hydroxyproline in animal metabolism, nutrition, and cell signaling.

Authors:  Shengdi Hu; Wenliang He; Guoyao Wu
Journal:  Amino Acids       Date:  2021-08-03       Impact factor: 3.520

9.  Spontaneously metastasizing variants derived from MNU-induced rat mammary tumour.

Authors:  J C Williams; B A Gusterson; R C Coombes
Journal:  Br J Cancer       Date:  1982-04       Impact factor: 7.640

10.  An integrative histopathologic clustering model based on immuno-matrix elements to predict the risk of death in malignant mesothelioma.

Authors:  Marcelo Luiz Balancin; Walcy Rosolia Teodoro; Cecilia Farhat; Tomas Jurandir de Miranda; Aline Kawassaki Assato; Neila Aparecida de Souza Silva; Ana Paula Velosa; Roberto Falzoni; Alexandre Muxfeldt Ab'Saber; Anja C Roden; Vera Luiza Capelozzi
Journal:  Cancer Med       Date:  2020-05-11       Impact factor: 4.452

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.